220 related articles for article (PubMed ID: 16225511)
21. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
[TBL] [Abstract][Full Text] [Related]
22. Editorial comment.
Berglund RK
Urology; 2009 Nov; 74(5):1083; author reply 1084. PubMed ID: 19883829
[No Abstract] [Full Text] [Related]
23. Initial experience of intravesical gemcitabine for patients with high-risk superficial transitional cell carcinoma of the bladder following BCG failure.
Allchorne P; Lamb BW; Kinsella J; Shamash J; Green JS
Urol Nurs; 2014; 34(2):95-9. PubMed ID: 24919248
[TBL] [Abstract][Full Text] [Related]
24. Design and evaluation of an intravesical delivery system for superficial bladder cancer: preparation of gemcitabine HCl-loaded chitosan-thioglycolic acid nanoparticles and comparison of chitosan/poloxamer gels as carriers.
Şenyiğit ZA; Karavana SY; İlem-Özdemir D; Çalışkan Ç; Waldner C; Şen S; Bernkop-Schnürch A; Baloğlu E
Int J Nanomedicine; 2015; 10():6493-507. PubMed ID: 26508855
[TBL] [Abstract][Full Text] [Related]
25. Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladder.
Maffezzini M; Campodonico F; Canepa G; Capponi G; Fontana V
Eur Urol; 2007 Apr; 51(4):956-61. PubMed ID: 17027141
[TBL] [Abstract][Full Text] [Related]
26. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study.
Laufer M; Ramalingam S; Schoenberg MP; Haisfield-Wolf ME; Zuhowski EG; Trueheart IN; Eisenberger MA; Nativ O; Egorin MJ
J Clin Oncol; 2003 Feb; 21(4):697-703. PubMed ID: 12586808
[TBL] [Abstract][Full Text] [Related]
27. [Double-mutated oncolytic adenovirus combined with gemcitabine for treating an orthotopic nude mouse model of bladder cancer].
Wang H; Liu Z; Wang ZP; Li FY; Zhao Y; Chen GP; Li DC
Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):412-7. PubMed ID: 24119899
[TBL] [Abstract][Full Text] [Related]
28. Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review.
Han MA; Maisch P; Jung JH; Hwang JE; Narayan V; Cleves A; Hwang EC; Dahm P
Investig Clin Urol; 2021 Nov; 62(6):623-630. PubMed ID: 34729962
[TBL] [Abstract][Full Text] [Related]
29. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC).
Gontero P; Casetta G; Maso G; Sogni F; Pretti G; Zitella A; Frea B; Tizzani A
Eur Urol; 2004 Sep; 46(3):339-43. PubMed ID: 15306105
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine doublets in advanced pancreatic cancer: should we move on?
Rocha Lima CM; Flores AM
J Clin Oncol; 2006 Jan; 24(3):327-9. PubMed ID: 16344312
[No Abstract] [Full Text] [Related]
31. [Role of gemcitabine in treatment of metastatic breast cancer].
Latipova DKh; Semiglazova TIu; Filatova LV; Gershanovich ML
Vopr Onkol; 2011; 57(2):139-46. PubMed ID: 21809657
[No Abstract] [Full Text] [Related]
32. Toxic epidermal necrolysis associated with gemcitabine therapy in a patient with metastatic transitional cell carcinoma of the bladder.
Mermershtain W; Cohen AD; Lazarev I; Grunwald M; Ariad S
J Chemother; 2003 Oct; 15(5):510-1. PubMed ID: 14598945
[TBL] [Abstract][Full Text] [Related]
33. Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer.
Palou J; Carcas A; Segarra J; Duque B; Salvador J; Garcia-Ribas I; Villavicencio H
J Urol; 2004 Aug; 172(2):485-8. PubMed ID: 15247710
[TBL] [Abstract][Full Text] [Related]
34. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study.
Bartoletti R; Cai T; Gacci M; Giubilei G; Viggiani F; Santelli G; Repetti F; Nerozzi S; Ghezzi P; Sisani M;
Urology; 2005 Oct; 66(4):726-31. PubMed ID: 16230125
[TBL] [Abstract][Full Text] [Related]
35. Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience.
Mohanty NK; Nayak RL; Vasudeva P; Arora RP
Urol Oncol; 2008; 26(6):616-9. PubMed ID: 18367121
[TBL] [Abstract][Full Text] [Related]
36. [The not-infrequent story of a superficial bladder carcinoma...Discussion of clinical case no.2].
Gontero P
Arch Ital Urol Androl; 2006 Dec; 78(4 Suppl 1):11-2. PubMed ID: 17491550
[No Abstract] [Full Text] [Related]
37. Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment.
Castagneto B; Zai S; Marenco D; Bertetto O; Repetto L; Scaltriti L; Mencoboni M; Ferraris V; Botta M
Oncology; 2004; 67(1):27-32. PubMed ID: 15459492
[TBL] [Abstract][Full Text] [Related]
38. Intravesical gemcitabine: a phase 1 and pharmacokinetic study.
Witjes JA; van der Heijden AG; Vriesema JL; Peters GJ; Laan A; Schalken JA
Eur Urol; 2004 Feb; 45(2):182-6. PubMed ID: 14734004
[TBL] [Abstract][Full Text] [Related]
39. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.
Sternberg IA; Dalbagni G; Chen LY; Donat SM; Bochner BH; Herr HW
J Urol; 2013 Nov; 190(5):1686-91. PubMed ID: 23665400
[TBL] [Abstract][Full Text] [Related]
40. Severe neurotoxicity caused by gemcitabine treatment.
Larsen FO; Hansen SW
Acta Oncol; 2004; 43(6):590-1. PubMed ID: 15370618
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
